About the work
Dr. Luis CRUZ RODRIGUEZ developed a following work:
A new coronavirus named Covid-19 was reported in Wuhan, China in December 2019. The first time these cases were published
they were classified as “pneumonia of unknown etiology”. The etiology of this illness is now attributed to a novel virus belonging
to the coronavirus (CoV) family, COVID-19. Different from both MERS-CoV and SARS-CoV, 2019-nCoV it is the seventh
member of the family of coronaviruses to infect humans. We have designed a preventive vaccine in Silico aimed to protect against
Covid-19 infection and transmission. Our analysis identified 16 microRNA (miRNA) with theorical Exosome Affinity (EA)
with peptide among 85.44-92.84 range. According to antiviral monitoring after and before vaccination using the candidate
miRNA-peptide number 13 (LCR_2020_B008-13) with value EA=92.84 Ro. We proposed the exosomes as biomarkers of
SARS-Covid-2 in lung: after and before vaccination. Due to, the miRNA-peptides, in Silico, manifesting highly affinity with
exosomes, where our chimera LCR_2020_B008-13 could reach a representative activity against the Covid-19 virogenes due
to “exosome sequestering”; and also, the treatment of cancer diseases due to “podosome depletion” in metastasis stage
Print work information
Work information
Title A-miRNA-PEPTIDE-FUSION-AS-A-VACCINE-CANDIDATE-AGAINST_COVID-19. EXOSOMES AS POTENTIAL BIOMARKERS OF SARS-COV-2 IN LUNG: AFTER AND BEFORE VACCINATION LCR_2020_B008-13
Dr. Luis CRUZ RODRIGUEZ developed a following work:
A new coronavirus named Covid-19 was reported in Wuhan, China in December 2019. The first time these cases were published
they were classified as “pneumonia of unknown etiology”. The etiology of this illness is now attributed to a novel virus belonging
to the coronavirus (CoV) family, COVID-19. Different from both MERS-CoV and SARS-CoV, 2019-nCoV it is the seventh
member of the family of coronaviruses to infect humans. We have designed a preventive vaccine in Silico aimed to protect against
Covid-19 infection and transmission. Our analysis identified 16 microRNA (miRNA) with theorical Exosome Affinity (EA)
with peptide among 85.44-92.84 range. According to antiviral monitoring after and before vaccination using the candidate
miRNA-peptide number 13 (LCR_2020_B008-13) with value EA=92.84 Ro. We proposed the exosomes as biomarkers of
SARS-Covid-2 in lung: after and before vaccination. Due to, the miRNA-peptides, in Silico, manifesting highly affinity with
exosomes, where our chimera LCR_2020_B008-13 could reach a representative activity against the Covid-19 virogenes due
to “exosome sequestering”; and also, the treatment of cancer diseases due to “podosome depletion” in metastasis stage
Work type Software and Database designs
Tags luis cruz rodriguez`s patent rights of covid-19 v
-------------------------
Registry info in Safe Creative
Identifier 2005304195207
Entry date May 30, 2020, 3:12 PM UTC
License Creative Commons Attribution 4.0
-------------------------
Copyright registered declarations
Author. Holder Luis CRUZ RODRIGUEZ. Date May 30, 2020.
Information available at https://www.safecreative.org/work/2005304195207-a-mirna-peptide-fusion-as-a-vaccine-candidate-against_covid-19-exosomes-as-potential-biomarkers-of-sars-cov-2-in-lung-after-and-before-vaccination-lcr_2020_b008-13
/
Registration: 2005304195207
